News

Specifically designed as a supplement for biological drug production, including biosimiliars, EX-CELL Glycosylation Adjust (Gal+) allows users to easily achieve desired N-linked glycosylation by increasing the galactose site

This is the first time in the current Ebola outbreak that EMA has given ‘rapid scientific advice’ using an accelerated procedure. EMA established this procedure to contribute to

The approval, issued in September 2014, allows Plandaí to grow cannabis in conjunction with the University, for medical research, which will be undertaken by students and scientists from

This financing was co-led by three new investors including AJU IB Investment Co., Ltd. and two undisclosed private investment groups. The round also includes full participation by all

XmAb5871 is a first-in-class monoclonal antibody containing Xencor’s proprietary immune inhibitor XmAb Fc domain that targets Fc?RIIb to inhibit B-cell function. XmAb5871 is currently in a Phase 1b/2a

Carried out in agreement to a post-marketing requirement by the US Food and Drug Administration (FDA), the trial showed comparable sexual function in these adults treated daily with

As part of the supplemental deal, Triphase will receive additional development funds through a cost sharing arrangement with Celgene. The deal will see Triphase control product development and

Following approval, this product will serve as replacement therapy for patients who suffer from a congenital lack of the normal plasminogen protein and/or its functional activity. The FDA

OliPass is focused on developing antisense medicines based on peptide nucleic acid (PNA) technology. As part of the deal, BMS will make an up-front payment as well as